Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Large-Vessel Involvement Is an Independent Risk Factor Predicting GCA Mortality

  |  

Carina Stanton is a freelance science journalist based in Denver.

References

ADVERTISEMENT
SCROLL TO CONTINUE
  1. Macchioni P, Boiardi L, Muratore F. et al. Survival predictors in biopsy-proven giant cell arteritis: A northern Italian population-based study. Rheumatology (Oxford). 2018 Dec 4. [Epub ahead of print]
  2. Hill CL, Black RJ, Nossent JC, et al. Risk of mortality in patients with giant cell arteritis: A systematic review and meta-analysis. Semin Arthritis Rheum. 2017 Feb;46(4):513–519.
  3. Kermani TA, Warrington KJ, Crowson CS, et al. Large-vessel involvement in giant cell arteritis: A population-based cohort study of the incidence-trends and prognosis. Ann Rheum Dis. 2013 Dec;72(12):1989–1994.
  4. Kermani TA, Warrington KJ. Prognosis and monitoring of giant cell arteritis and associated complications. Expert Rev Clin Immunol. 2018 May;14(5):379–388.

Related Articles

    Updates on Giant Cell Arteritis

    SAN DIEGO—Recent research tells us more about giant cell arteritis (GCA) to help rheumatologists more accurately diagnose and effectively treat patients with this type of vasculitis. On Nov. 6 at the ACR/ARHP Annual Meeting, three experts explored the latest findings on GCA pathogenesis, diagnostic approaches, imaging modalities and growing treatment options. GCA: What’s Really Happening?…

    Experts Discuss Proposed Giant Cell Arteritis Risk Tool

    A proposed model to predict the risk of giant cell arteritis (GCA) prior to a temporal artery biopsy could help triage patients and guide decision making about the need for biopsy or monitoring (see Figure 1). There’s no specific biomarker for GCA, and GCA can be a “diagnostic conundrum, especially when it presents in an…